(Invited) Development of Leuco Ethyl Violet as Self-Activating Prodrug Photooxygenation Catalyst of Amyloid-β

Abnormal aggregation of amyloid-β (Aβ) and tau protein (tau), called amyloid, is characteristic of Alzheimer's disease (AD). Reducing amyloid levels in AD patients is expected to be an effective approach to AD treatment. To inhibit the hydrophobic interaction of amyloid, which is the cause of toxic aggregates, we planed to generate singlet oxygen by activating oxygen in vivo through photocatalysis, thereby introducing oxygen atoms to amyloid protein and inhibiting aggregation. In accordance with this concept, we are developing photooxygenation catalysts with a switch function that generates singlet oxygen only in the presence of amyloids. We have succeeded in reducing amyloid in AD model mouse brain non-invasively with this photo-oxygenation catalyst. However, moderate catalytic activity and the side effect of scalp damage have been problematic. This time, we identified leucoethyl violet (LEV) as a highly active, amyloid-selective, blood-brain barrier (BBB)-permeable photooxygenation catalyst. LEV is a self-activating procatalyst by external redox stimuli. Autoxidation of LEV by a hydrogen atom transfer process under light irradiation produced active catalyst species Ethyl Violet (EV) only in the presence of amyloids. LEV showed higher catalytic activity than the previously developed photooxygenation catalyst and realized oxygenation of human Aβ and tau. Taking advantage of LEV's high activity and amyloid selectivity, improved BBB permeability, and low cytotoxicity, photooxygenation of Aβ was achieved in an AD model without scalp injury. Figure 1